Auriga Partners

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

Patrowl is an innovative product designed by cybersecurity experts. It automates the detection and remediation of your vulnerabilities to finally be faster and more efficient than cybercriminal organizations. It is built around 4 main principles: - Thanks to Artificial Intelligence coupled with our expertise, Patrowl automates continuous penetration tests. This allows us to identify your assets (known and shadow-it) and vulnerabilities in real time over a wide area. - At a glance, visualize your overall level of security and especially how to improve it. - Real adapted solutions appear on the Dashboard. You will be able to act yourself or quickly transmit the solution directly to the teams concerned and follow the remediation. - Then Patrowl lets you make sure everything has been fixed with one click, by retesting. This solution is simple, easy to learn and makes cybersecurity accessible to everyone. Our watchword: demotivate cybercriminals

Vade Secure is a leader in cybersecurity specializing in anti-phishing, spear phishing, malware, and ransomware protection through advanced heuristic filtering. The company's technology analyzes incoming emails, including links, attachments, and content, to identify and neutralize threats, even zero-day attacks and highly targeted scams. Vade Secure also addresses the issue of low-priority emails through its Graymail Management feature, which automatically sorts ads, social media notifications, and newsletters into a separate folder while providing a Safe Unsubscribe option to eliminate them permanently. With over 500 million mailboxes protected in 76 countries, Vade Secure's solutions are trusted by major ISPs, OEMs, and enterprises globally. The company operates in five countries—USA, Canada, France, Hong Kong, and Japan—and provides round-the-clock support to its clients.

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

Flash Therapeutics is a biotechnology company based in Labège, France, focused on developing gene and cell-based therapies utilizing its proprietary lentiviral platform. The company specializes in creating lentiviral vectors that facilitate the transduction of hard-to-transfect cells, including primary and stem cells, as well as in vivo tissues. Its offerings encompass a range of services such as gene silencing, gene over-expression, cell-based assay development, protein expression, and production. Flash Therapeutics also engages in preclinical trials for gene therapy and manufactures ready-to-use lentiviral particles for cell reprogramming and fluorescent protein expression. Additionally, the company produces highly concentrated and purified viral vectors and develops predictive experimental cellular models and genetically modified animals, employing both non-integrative and integrative technologies. Originally established in 2005 as Vectalys SAS, it rebranded to Flash Therapeutics in January 2018.

EnobraQ, founded in 2015 as a start-up emerging from a pre-competitive research initiative supported by Toulouse White Biotechnology, focuses on innovative technologies that utilize CO2 as a feedstock for industrial fermentation. The company's efforts are driven by ecological and economic considerations, targeting a diverse array of markets including nutrition, agri-food, cosmetics, pharmacology, and bioplastics. By developing breakthrough methods to transform CO2 into valuable products, EnobraQ aims to contribute to sustainable practices across various industries.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

VitaDX is a startup focused on enhancing cancer diagnosis through the application of artificial intelligence and fluorescence imaging technology. Its primary product, VisioCyt®, is designed for the early detection of bladder cancer, utilizing a simple urine sample to improve upon the traditional urinary cytology methods. By integrating machine learning with advanced imaging techniques, VitaDX aims to identify potential abnormalities in the urinary excretory tract. This innovative approach enables healthcare providers to offer more accurate and timely cancer diagnostic services, ultimately leading to improved treatment options and better patient outcomes.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Senders™ is a contextual intelligence email service offered by One More Company, Inc, the company behind Trackbuster™, which offered the same email untracking features now available as part of Senders. Senders is the latest product from One More Company. It functions like Caller ID for email by providing the recipient more information about the sender right in the email, so it works everywhere, regardless of app, platform, and device. Senders™ is a patent-pending service designed and securely hosted in the US. They are focused on enhancing the email experience for individuals and businesses by helping users filter the messaging signal from the noise and providing relevant information on the fly, in an open way. They provide simple, intuitive services around messaging and the cloud. They are driven by a digital ethics based on consumer control, privacy, and transparency. Their users are their customers and their interests are paramount. Their business model is not based on selling ads, or collecting and selling data. At One More Company, Inc., creating a positive consumer experience is their highest priority, and their raison d’être. Their products are designed to make life easier. They can’t do that without ensuring user privacy and the security of personal information. So, they think about privacy and security from the beginning, and throughout the product design process; in other words, privacy by design. One More Company, Inc is a U.S. corporation founded by seasoned executives with decades of experience in Silicon Valley, at places like Google, Facebook, Twitter, and IBM. It has offices in New York and Paris. Senders™ is a patent-pending service designed and securely hosted in the USA.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Theranexus is a clinical-stage biopharmaceutical company based in France, focused on developing innovative drug candidates for central nervous system (CNS) disorders. The company aims to address significant medical needs in brain disorders by creating combinations of two distinct drugs: one targeting neuronal activity and the other focusing on glial cells. Its key drug candidates include THN102, designed to treat excessive daytime sleepiness in Parkinson's disease; THN201, aimed at addressing neurocognitive disorders associated with Alzheimer's disease; and THN101, which targets neuropathic pain. Through its unique therapeutics platform, Theranexus seeks to enhance treatment efficacy for various CNS conditions.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Amoeba is a France-based company dedicated to the development, production, and commercialization of green biocide water treatment chemicals for the industrial sector. Its primary product, BIOMEBA, utilizes the biocidal properties of Willaertia magna to effectively address bacterial risks in cooling towers. By focusing on environmentally friendly solutions, Amoeba aims to provide sustainable alternatives in water treatment, enhancing safety and efficiency in industrial applications.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Wallix is a France-based cybersecurity software company specializing in privileged access management solutions under the WALLIX Bastion brand. The company addresses the growing need for cyber security in response to regulatory changes and evolving threats, helping users protect critical IT assets such as data, servers, terminals, and connected devices. Its solutions include modules for session management, which monitors privileged users' access and sessions in real-time to prevent malicious activity; a password manager that allows super-administrators to maintain control over access governance; and an access manager that provides a comprehensive overview of privileged users' logins and actions to mitigate risks. Wallix has earned recognition for its security measures, being the first to receive a first-level security certification from France’s National Cybersecurity Agency. The company serves over 770 clients across various sectors, including notable organizations like Alain Afflelou, Dassault Aviation, and McDonald's, and distributes its solutions through a network of more than 160 resellers and accredited integrators across Europe and EMEA.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

eXo Platform SAS is a provider of Java middleware and open-source digital collaboration software based in Paris, France, with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company offers a range of solutions designed to facilitate collaboration and knowledge sharing within organizations. Its flagship product, eXo Platform, allows users to build enterprise social networks, websites, and social intranets, while other offerings include eXo Portal for centralized access to content, eXo Wallet for digital transactions, and various tools for document and content management. eXo's software also supports workflow design, project collaboration, and knowledge capital organization. Serving a diverse clientele across sectors such as government, financial services, and telecommunications, eXo has established strategic partnerships with notable companies like Red Hat, Capgemini, and Atos Origin to enhance its market presence.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Firalis is a biotechnology company specializing in the discovery, development, and regulatory qualification of novel biomarkers aimed at enhancing diagnostics for various diseases. The company focuses on biomarkers related to inflammatory disorders, including common conditions like atherosclerosis and rheumatoid arthritis, as well as rare diseases such as systemic or autoimmune vasculitis. Firalis is particularly invested in addressing drug-induced organ injuries in major targets like the kidneys, liver, and vasculature. By leveraging a unique network of clinical centers of excellence, Firalis conducts biomarker qualification studies to ensure high success potential for its diagnostic kits. The company is headquartered in Huningue, France, strategically located in BioValley, which is known for its proximity to significant pharmaceutical hubs in Europe. Through its innovative biomarker services, Firalis aims to improve patient outcomes, enhance therapeutic decisions, and reduce overall healthcare costs.

Miliboo is a furniture brand that designs and offers a wide array of contemporary furniture products, including sofas, armchairs, bar stools, office chairs, tables, storage solutions, and garden furniture. Founded in 2005, the company is based in Pringy, France. Miliboo's product portfolio also features furniture for children and decorative items such as table lamps. The company is committed to providing stylish and functional furniture for various settings, catering to both residential and commercial needs.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Codenvy offers a cloud development platform that facilitates coding, building, and testing applications. By moving the local desktop workspace—comprising the editor, builder, and tester runtimes—into the cloud, Codenvy allows enterprises to access on-demand workspaces that promote collaboration and eliminate physical constraints. This innovative approach enhances the development process by providing a flexible and efficient environment tailored for modern software development needs.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Wallix is a France-based cybersecurity software company specializing in privileged access management solutions under the WALLIX Bastion brand. The company addresses the growing need for cyber security in response to regulatory changes and evolving threats, helping users protect critical IT assets such as data, servers, terminals, and connected devices. Its solutions include modules for session management, which monitors privileged users' access and sessions in real-time to prevent malicious activity; a password manager that allows super-administrators to maintain control over access governance; and an access manager that provides a comprehensive overview of privileged users' logins and actions to mitigate risks. Wallix has earned recognition for its security measures, being the first to receive a first-level security certification from France’s National Cybersecurity Agency. The company serves over 770 clients across various sectors, including notable organizations like Alain Afflelou, Dassault Aviation, and McDonald's, and distributes its solutions through a network of more than 160 resellers and accredited integrators across Europe and EMEA.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Eptica S.A. is a company based in Boulogne-Billancourt, France, specializing in customer relationship management (CRM) software aimed at business-to-business (B2B) marketplaces. Established in 2001, Eptica develops solutions that enhance real-time interactions between enterprises and their clients, suppliers, and partners through various digital channels. Its offerings include multi-channel communications, self-service options, and tools for email management and knowledge sharing. Eptica also provides consulting, technical support, and training services to clients across sectors such as banking, insurance, retail, tourism, and public institutions. By integrating artificial intelligence, Eptica aims to transform digital relationships into meaningful exchanges, ultimately improving customer engagement and operational efficiency. The company operates as a subsidiary of Enghouse Systems Limited.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Neolane, Inc. is a provider of conversational marketing technology that specializes in marketing automation and cross-channel campaign management software for both business-to-business and business-to-consumer marketers. The company enables organizations to create and maintain one-to-one lifetime dialogues with their customers, enhancing revenue generation and marketing efficiency. Neolane has demonstrated significant growth, recording $58 million in revenue in 2012, which represented a 40% increase from the previous year. The company has received recognition for its innovative approach, being named #64 on Forbes' list of America's Most Promising Companies in 2013. Neolane's technology is utilized by over 400 leading global companies, including Alcatel Lucent, Barnes & Noble, Orange, Sears Canada, Sephora Europe, and Sony Music, helping them navigate customer engagement challenges effectively.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Wallix is a France-based cybersecurity software company specializing in privileged access management solutions under the WALLIX Bastion brand. The company addresses the growing need for cyber security in response to regulatory changes and evolving threats, helping users protect critical IT assets such as data, servers, terminals, and connected devices. Its solutions include modules for session management, which monitors privileged users' access and sessions in real-time to prevent malicious activity; a password manager that allows super-administrators to maintain control over access governance; and an access manager that provides a comprehensive overview of privileged users' logins and actions to mitigate risks. Wallix has earned recognition for its security measures, being the first to receive a first-level security certification from France’s National Cybersecurity Agency. The company serves over 770 clients across various sectors, including notable organizations like Alain Afflelou, Dassault Aviation, and McDonald's, and distributes its solutions through a network of more than 160 resellers and accredited integrators across Europe and EMEA.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France.

Founded in 2001, Availpro is a prominent provider of e-booking software solutions designed to enhance hotel occupancy and revenue while reducing costs. The company offers a fully integrated online distribution system that enables hotel owners to manage all aspects of their operations, from hotel management to distribution channels. Availpro equips managers with innovative tools to optimize pricing, maximize commission-free bookings through official websites, and streamline decision-making processes. The company has developed extensive expertise in creating connectivity solutions that link various software platforms, partnering with over 300 companies worldwide, including major online travel agencies and global distribution systems. This commitment to simplifying the distribution process and enhancing efficiency positions Availpro as a reliable and high-performance tool for the hospitality industry. With a dedicated international team of 75 professionals, Availpro continues to focus on delivering effective solutions for its clients.

CellNovo is a medical device company focused on diabetes management. The company develops and markets a comprehensive system that includes a cordless micro-pump, an integrated monitoring device, and a cellular handset with a touch screen and embedded blood glucose meter. This innovative system facilitates the automatic transmission of data, allowing for real-time monitoring of patients' conditions through mobile connectivity. By creating an interconnected diabetes management solution, CellNovo aims to enhance the quality of care for individuals living with diabetes.

Miliboo is a furniture brand that designs and offers a wide array of contemporary furniture products, including sofas, armchairs, bar stools, office chairs, tables, storage solutions, and garden furniture. Founded in 2005, the company is based in Pringy, France. Miliboo's product portfolio also features furniture for children and decorative items such as table lamps. The company is committed to providing stylish and functional furniture for various settings, catering to both residential and commercial needs.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

Nexthink S.A. is a leader in end-user experience management, providing a real-time analytics platform that enhances productivity by transforming endpoint analytics and user feedback into actionable insights. Founded in 2004 and headquartered in Prilly, Switzerland, the company serves a diverse range of industries, including education, finance, healthcare, and manufacturing, among others. Nexthink's solutions include incident and problem management, change management, and integration options, all designed to improve the digital workplace experience. Its Digital Experience Score system combines quantitative data with user feedback, allowing organizations to measure and enhance their digital environments. With operations extending across the United States, Europe, the Middle East, and Asia Pacific, Nexthink empowers IT teams to address the challenges of the modern digital workplace through advanced analytics, automation, and machine learning.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Ekinops is a provider of advanced optical transport solutions aimed at service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which supports metro, regional, and long-haul applications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G technologies, that enhance data transport capacity over various network infrastructures such as dark fiber, CWDM, DWDM, SONET/SDH, IP, and SAN networks. By leveraging expertise in transmission, aggregation, and forward error correction, Ekinops enables operators to optimize their optical networks in a cost-effective manner.

Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.

eXo Platform SAS is a provider of Java middleware and open-source digital collaboration software based in Paris, France, with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company offers a range of solutions designed to facilitate collaboration and knowledge sharing within organizations. Its flagship product, eXo Platform, allows users to build enterprise social networks, websites, and social intranets, while other offerings include eXo Portal for centralized access to content, eXo Wallet for digital transactions, and various tools for document and content management. eXo's software also supports workflow design, project collaboration, and knowledge capital organization. Serving a diverse clientele across sectors such as government, financial services, and telecommunications, eXo has established strategic partnerships with notable companies like Red Hat, Capgemini, and Atos Origin to enhance its market presence.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Evolva is a biotechnology company based in Reinach, Switzerland, founded in 2004. The company specializes in the research, development, and commercialization of nature-based ingredients that are ready for formulation. Utilizing a proprietary synthetic biology platform, Evolva creates innovative small-molecule compounds that replicate the beneficial properties of natural products while mitigating their disadvantages. Their offerings find applications in various sectors, including flavors and fragrances, health ingredients, and health protection. Through its advanced technology, Evolva aims to provide high-quality ingredients that meet the needs of diverse industries.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Evolva is a biotechnology company based in Reinach, Switzerland, founded in 2004. The company specializes in the research, development, and commercialization of nature-based ingredients that are ready for formulation. Utilizing a proprietary synthetic biology platform, Evolva creates innovative small-molecule compounds that replicate the beneficial properties of natural products while mitigating their disadvantages. Their offerings find applications in various sectors, including flavors and fragrances, health ingredients, and health protection. Through its advanced technology, Evolva aims to provide high-quality ingredients that meet the needs of diverse industries.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Cytoo SA is a life sciences company based in Grenoble, France, specializing in micropattern-enhanced cell-based assays. Founded in 2008, the company develops, manufactures, and commercializes innovative technologies for cell analysis aimed at the life sciences research community. Cytoo's product offerings include CYTOO chips, which feature glass coverslip formats with micropatterns for research applications, and CYTOOchips Mini, designed as standard glass bottom microplates. Additionally, the company provides CYTOOplates with adhesive micropatterns for immunofluorescence assays and CYTOOchambers for high-resolution timelapse live microscopy. These solutions facilitate a variety of research areas, including cell shape analysis, cytoskeletal dynamics, and quantitative cell phenotyping. Cytoo also offers assay development services, focusing on enhancing the reliability and robustness of cellular analysis while addressing the specific needs of researchers.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Bonitasoft, a software company based in Grenoble, France, specializes in open source business process management (BPM) solutions. The company offers the Bonita platform, which facilitates the design, development, execution, and monitoring of business processes. This platform includes tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for service integration. Bonitasoft also provides a cloud-based version of its BPM solution, allowing developers to build and run applications in various environments. Its offerings extend to human resources, corporate finance, quality management, and IT management solutions. The company caters to a diverse range of industries, including education, energy, financial services, healthcare, manufacturing, public sector, retail, and telecommunications. Additionally, Bonitasoft provides support services that encompass the design, development, deployment, and training of BPM applications. Founded in 2001, Bonitasoft has expanded its presence with offices in San Francisco and other locations in France.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.

Ekinops is a provider of advanced optical transport solutions aimed at service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which supports metro, regional, and long-haul applications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G technologies, that enhance data transport capacity over various network infrastructures such as dark fiber, CWDM, DWDM, SONET/SDH, IP, and SAN networks. By leveraging expertise in transmission, aggregation, and forward error correction, Ekinops enables operators to optimize their optical networks in a cost-effective manner.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Bag Tech specializes in the development, design, and manufacturing of a diverse range of bags and backpacks. The company produces practical and durable products at wholesale prices, utilizing a facility in Sialkot, Pakistan, which spans over 10,000 square feet. Skilled craftsmen employ modern technology to ensure meticulous care in the manufacturing process. Bag Tech's product lineup includes various types of bags such as kit bags, travel kits, sports kits (including cricket, hockey, boxing, and karate), gym bags, school bags, backpacks, and specialized bags for helmets, shoes, and laptops. Additionally, the company offers protective covers for sports equipment and a selection of ladies' bags, catering to a wide array of customer needs.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Ekinops is a provider of advanced optical transport solutions aimed at service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which supports metro, regional, and long-haul applications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G technologies, that enhance data transport capacity over various network infrastructures such as dark fiber, CWDM, DWDM, SONET/SDH, IP, and SAN networks. By leveraging expertise in transmission, aggregation, and forward error correction, Ekinops enables operators to optimize their optical networks in a cost-effective manner.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.

Streamcore is a leading provider of visibility and dynamic performance control solutions for managing interactive applications and real-time communications (VoIP, video…) delivery over the WAN. Streamcore products enable enterprises to benefit from all-in-one visibility - network, applications, VoIP, video -, real-time monitoring and advanced on-demand reporting from a single centralized management console. What makes Streamcore solutions unique is that visibility and advanced performance control are tied together and can be enabled from data centers to ensure fast deployment and cost-efficiency.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.